Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA Identifies Problems to Improve Its Services
June 19, 2006
- Torrent of India Starts Business in Japan
June 19, 2006
- REGULATORY NEWS IN BRIEF
June 19, 2006
- JGPMA Drafting Model for GE Drug
June 19, 2006
- NEW PRODUCTS
June 19, 2006
- JGPMA Makes 5 Proposals
June 19, 2006
- MBC Gearing Up for Global Clinical Trials
June 19, 2006
- 3 of 4 Doctors Unsatisfied with GE Drugs
June 19, 2006
- American Society of Clinical Oncology (ASCO) 2006: 1
June 19, 2006
- Most Doctors See Problems
June 19, 2006
- R&D NEWS IN BRIEF
June 19, 2006
- GENERIC NEWS IN BRIEF
June 19, 2006
- Drug-Eluting Stents Prevent
June 19, 2006
- Korosho to Work Out New Industry Vision
June 19, 2006
- MEDICAL DEVICE NEWS IN BRIEF
June 19, 2006
- Consent Not Obtained for Insulin
June 19, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 19, 2006
- SURVEY an article
June 12, 2006
- JAPIC Regulatory Affairs Seminar
June 12, 2006
- OPINION
June 12, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…